Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5404868 | 0.76 | CTSK (0.36) | SMN1; SMN2 | |
| SCHEMBL17152527 | 0.76 | CYP2C19 (0.38) | SMN1; SMN2P2RX7CYP2C19 | |
| SCHEMBL6686841 | 0.74 | CTSK (0.40) | HTTCYP2C19 | |
| SCHEMBL6685637 | 0.71 | CTSK (0.41) | — | |
| SCHEMBL2859765 | 0.71 | CYP2C19 (0.36) | SMN1; SMN2CYP2C19 | |
| SCHEMBL14889774 | 0.70 | CYP2C19 (0.30) | CYP2C19 | |
| SCHEMBL630218 | 0.70 | CYP2C19 (0.39) | SMN1; SMN2P2RX7CYP2C19 | |
| SCHEMBL3154827 | 0.69 | NAMPT (0.40) | CYP2C19 | |
| SCHEMBL15059607 | 0.68 | CYP2C19 (0.35) | CYP2C19 | |
| SCHEMBL1231768 | 0.68 | CYP2C19 (0.40) | SMN1; SMN2P2RX7CYP4F2CYP4A11CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7109243-B2 | Inhibitors of cathepsin S | IRM LLC (BM) | 2006-09-19 | — | — | US | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | HTT 396/4885SMN1; SMN2 3203/4885P2RX7 2370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.